Showing results (201-210 of 215) with videos related to

Sort By:
Pageof 22
American Journal of Hematology|March 23, 2021
Effect of age and frailty on the efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myelomaHolger W Auner, Maria Gavriatopoulou, Sosana Delimpasi, et al.
Blood Advances|August 19, 2025
Prospective real-world evaluation of t(11;14) prevalence and disease biology in multiple myeloma: MEDICI study analysisAndrew Spencer, Maria Gavriatopoulou, Daniel Coriu, et al.
American Journal of Hematology|June 1, 2021
Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic riskShambavi Richard, Ajai Chari, Sosana Delimpasi, et al.
The Lancet. Haematology|June 28, 2025
Optimising T-cell immunotherapy in patients with multiple myeloma: practical considerations from the European Myeloma NetworkNiels W C J van de Donk, Philippe Moreau, Jesús F San-Miguel, et al.
Blood|December 17, 2025
Selective depletion of B-cell subsets underlies increased risk of infection in MM patients treated with anti-BCMA vs -GPRC5D bsAbsTomas Jelinek, David Žihala, Aintzane Zabaleta, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 14, 2021
Consolidation and Maintenance in Newly Diagnosed Multiple MyelomaPieter Sonneveld, Meletios A Dimopoulos, Meral Beksac, et al.
The New England Journal of Medicine|June 3, 2024
Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple MyelomaVania Hungria, Pawel Robak, Marek Hus, et al.
Hemasphere|November 27, 2025
Sequencing BCMA- and GPRC5D-targeting immunotherapies in multiple myeloma: Practical guidance from the European Myeloma NetworkNiels W C J van de Donk, Philippe Moreau, Jesus F San-Miguel, et al.
The New England Journal of Medicine|December 12, 2023
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple MyelomaPieter Sonneveld, Meletios A Dimopoulos, Mario Boccadoro, et al.
Future Oncology (London, England)|September 17, 2024
A plain language summary of the PERSEUS study of daratumumab plus bortezomib, lenalidomide, and dexamethasone for treating newly diagnosed multiple myelomaPieter Sonneveld, Meletios A Dimopoulos, Mario Boccadoro, et al.
Pageof 22